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Background: T674I FIP1L1-PDGFRα in a subset of chronic eosinophilic leukemia (CEL) is a gatekeeper mutation that
is resistant to many tyrosine kinase inhibitors (TKIs) (e.g., imatinib, nilotinib and dasatinib), similar to T315I Bcr-Abl.
Therefore, novel TKIs effective against T674I FIP1L1-PDGFRα are needed. Ponatinib (AP24534) is a novel orally
bioavailable TKI against T315I Bcr-Abl, but it is not clear whether ponatinib is effective against T674I FIP1L1-PDGFRα.
The purpose of this study was to examine the effect of ponatinib on T674I FIP1L1-PDGFRα.
Methods: Molecular docking analysis in silico was performed. The effects of ponatinib on PDGFRα signaling pathways,
apoptosis and cell cycling were examined in EOL-1, BaF3 cells expressing either wild type (WT) or T674I FIP1L1-PDGFRα. The
in vivo antitumor activity of ponatinib was evaluated with xenografted BaF3-T674I FIP1L1-PDGFRα cells in nude mice models.
Results: Molecular docking analysis revealed that ponatinib could bind to the DFG (Asp-Phe-Gly)-out state of T674I PDGFRα.
Ponatinib potently inhibited the phosphorylation of WT and T674I FIP1L1-PDGFRα and their downstream signaling molecules
(e.g., Stat3, Stat5). Ponatinib strikingly inhibited the growth of both WT and T674I FIP1L1-PDGFRα-carrying CEL cells
(IC50: 0.004–2.5 nM). It induced apoptosis in CEL cells with caspase-3-dependent cleavage of Mcl-1, and inhibited
tyrosine phosphorylation of β-catenin to decrease its stability and pro-survival functions. In vivo, ponatinib abrogated
the growth of xenografted BaF3-T674I FIP1L1-PDGFRα cells in nude mice.
Conclusions: Ponatinib is a pan-FIP1L1-PDGFRα inhibitor, and clinical trials are warranted to investigate its efficacy in
imatinib-resistant CEL.
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Platelet-derived growth factor receptor α (PDGFRα) is a
class III receptor tyrosine kinase with an extracellular
domain, a single transmembrane domain, and a cyto-
plasmic tyrosine kinase domain [1]. Upon ligand bind-
ing, the activated receptor drives multiple downstream
pathways such as signal transducer and activator of tran-
scription (Stat), Src kinases, mitogen-activated protein
kinases, and phosphatidylinositol-3 kinase to coordinate* Correspondence: panjx2@mail.sysu.edu.cn
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reproduction in any medium, provided the orcell proliferation, differentiation, survival, adhesion,
and cell migration [2]. Gain-of-function mutations in
PDGFRα have been found in chronic myeloid leukemia
(CML), gastrointestinal stromal tumors (GISTs) and chronic
eosinophilic leukemia (CEL) [3]. A typical example is the fu-
sion gene of FIP1-like 1 (FIP1L1)-PDGFRα created by an
800-kb cryptic interstitial deletion in chromosome 4q12,
which is pathogenic for a subset of CEL [1]. FIP1L1-
PDGFRα encodes a ligand-independent and constitutively
active tyrosine kinase that is sensitive to imatinib [4-6].
However, acquired resistance to imatinib can occur because
of point mutations in the ATP binding site (e.g., T674I and
D842V) [7-9]. T674I FIP1L1-PDGFRα is a “gatekeeper” mu-
tation: substitution of the gatekeeper threonine (T674) withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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second-generation tyrosine kinase inhibitors (TKIs), such as
nilotinib and dasatinib, to a hydrophobic pocket inside the
ATP binding site [10]. This gatekeeper mutation is analo-
gous to the T315I mutation in Bcr-Abl [1,5,11,12]. The
prognosis is poor for CEL patients harboring T674I FIP1L1-
PDGFRα although it is rare in incidence.
To search for novel TKIs to overcome imatinib resist-
ance, midostaurin, EXEL-0862 and sorafenib have been
investigated both in vitro and in vivo in cells harboring
T674I FIP1L1-PDGFRα [2,9,13]. Thus far, the first clin-
ical trial of sorafenib for T674I FIP1L1-PDGFRα-positive
CEL showed a transient hematological response, but
patients died of rapid emergence of additional sorafenib-
resistant point mutations in FIP1L1-PDGFRα [7]. Inde-
pendently, Metzgeroth et al. reported limited clinical
activity of sorafenib and nilotinib in T674I FIP1L1-
PDGFRα-positive CEL patients [14]. Therefore, imatinib-
resistant CEL remains a therapeutic challenge.
There has been exciting recent advance in third-
generation TKIs (ponatinib, HG-7-85-1 and DCC-2036) ef-
ficacious against the gatekeeper mutants [15-18]. In vitro
screening assay has demonstrated that ponatinib, the first
TKI effective against T315I Bcr-Abl, is also a potent inhibi-
tor of KIT, PDGFRα, Flt3, Src, VEGFR and FGFR [15,19,20].
We investigated the molecular docking of ponatinib to
T674I PDGFRα in silico. In vitro and in vivo study then
confirmed that ponatinib is a potent inhibitor of CEL
cells bearing wild-type (WT) or T674I FIP1L1-PDGFRα.
Results
Computer-simulated binding of ponatinib to the native or
mutated PDGFRα kinase in DFG(Asp-Phe-Gly)-out state
To gain insights into the structural basis for ponatinib to
bind to the ATP-binding site of T674I PDGFRα, we per-
formed computer simulations of molecular docking be-
tween ponatinib and T674I PDGFRα: ponatinib bound
to native or mutated PDGFRα with the same orientation
in the DFG-out state (Additional file 1: Figure S1A).
These findings were similar to those observed in the
complex between ponatinib and T315I Abl [15,21]. The
T674I gatekeeper mutation does not perturb the overall
protein structure of PDGFRα, except that the large ali-
phatic side chain causes a steric hindrance that prevents
the binding of imatinib but not ponatinib (data not
shown). The imidazo [1,2b] pyridazine scaffold of pona-
tinib docks in the adenine binding pocket of T674I
PDGFRα and forms one hydrogen bond with the backbone
N atom of C677 in the hinge region (distance 3.16 Å)
(Additional file 1: Figure S1B). The ethynylene linker makes
VDW interactions with the side chain of I674 residue, and
the methylphenyl group occupies the hydrophobic pocket
behind the gatekeeper residue. The extended amide linker
contacts T674I PDGFRα by 2 hydrogen bonds, one withthe backbone N atom of D836 (distance 3.76 Å) in the
DFG motif and the other with the side chain carboxyl of
E644 (distance 3.09 Å) in the C helix. Consequently,
the trifluoromethylphenyl group binds to the pocket in
the DFG-out conformation, with the terminal methyl-
piperazion group oriented to a solvent-exposed region.
Ponatinib and WT PDGFRα have an interaction profile
(Additional file 1: Figure S1C) similar to but slightly differ-
ent from that in Additional file 1: Figure S1B. Specifically,
the whole WT PDGFRα molecule turns more closely to
the DFG motif, with the corresponding H-bond distance
shortened to 2.92 Å. The in silico structural comparisons
revealed the importance of the DFG-out state and the
ethynylene linker in ponatinib in avoiding a steric clash
imposed by the mutated gatekeeper residue I674.
Ponatinib inhibits PDGFRα phosphorylation
To examine whether ponatinib is active against T674I
FIP1L1-PDGFRα, we exposed BaF3-T674I FIP1L1-PDGFRα
cells to ponatinib, sorafenib and imatinib (the latter two
serving as positive and negative controls, respectively);
levels of phosphorylated and total PDGFRα were mea-
sured by immunoblotting. The phosphorylation of T674I
FIP1L1-PDGFRα was altered by sorafenib but not ima-
tinib (Figure 1A), which is consistent with a previous re-
port [13]. In contrast to imatinib, 300 nM ponatinib
inhibited phosphorylation of T674I FIP1L1-PDGFRα to a
similar degree as 1000 nM sorafenib (Figure 1A). It also
inhibited the phosphorylation of FIP1L1-PDGFRα in
EOL-1, BaF3-WT FIP1L1-PDGFRα and BaF3-T674I
FIP1L1-PDGFRα cells in concentration- and time-
dependent manners (Figure 1B and C).
Ponatinib inhibits downstream signaling of PDGFRα
We next examined signal transduction downstream of
PDGFRα after ponatinib treatment. The phosphorylation of
Stat3, Stat5, Akt and Erk1/2 were measured by immunoblot-
ting with phospho-specific antibodies. Treatment for 24 h
with ponatinib reduced the phosphorylation of Stat3, Stat5,
Akt and Erk1/2 in cells expressing WT or T674I PDGFRα
at 0.3-30 nM (Figure 1D) and over time (Figure 1E).
Ponatinib inhibits growth of imatinib-resistant and -sensitive
CEL cells bearing PDGFRα
We examined the effect of TKIs on cell viability (MTS
assay). The three lines of FIP1L1-PDGFRα-expressing
cells were incubated with or without increasing concen-
trations of ponatinib, sorafenib, or imatinib for 72 h; log
concentration-response curves are shown in Figure 2A.
EOL-1 and BaF3-WT FIP1L1-PDGFRα cells were sensitive
to imatinib, with IC50 values of 0.3 and 2.8 nM, respect-
ively. BaF3-T674I FIP1L1-PDGFRα cells were resistant to
imatinib, similar to previous reports [1,2]. Ponatinib inhibited
the growth of all three FIP1L1-PDGFRα-expressing cell lines,
Figure 1 Ponatinib inhibits phosphorylation of PDGFRα and its downstream signaling molecules. (A) BaF3-T674I FIP1L1-PDGFRα cells exhibited
differential sensitivity to ponatinib and sorafenib. BaF3-T674I FIP1L1-PDGFRα cells were treated with the TKIs at the indicated concentrations for
24 h, and the levels of phosphorylated and total PDGFRα were detected with the relevant antibodies. (B) Ponatinib inhibited phosphorylation of
PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of
ponatinib for 24 h. (C) Ponatinib inhibited phosphorylation of PDGFRα in a time-dependent manner. The concentrations of ponatinib were 1 nM
for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells, respectively. (D) Ponatinib concentration-dependently inhibited phosphorylation
of Stat3, Stat5, Akt and Erk1/2. The cells were exposed to increasing concentrations of ponatinib for 24 h. (E) Ponatinib time-dependently
inhibited phosphorylation of Stat3, Stat5, Akt and Erk1/2. 300 nM ponatinib was applied.
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FIP1L1-PDGFRα cells were about 100-fold more sensitive to
ponatinib than to sorafenib (IC50 = 2.5 versus 250 nM,
respectively).
In another independent set of experiments, we evalu-
ated the impact of ponatinib on clonogenicity of the two
lines of BaF3 cells. Cells were exposed to increasing
concentrations of ponatinib for 24 h, then equal num-
bers of treated cells were seeded in methylcellulose
medium. Ponatinib concentration-dependently inhibitedthe number of clonogenic BaF3-WT or -T674I FIP1L1-
PDGFRα cells (Figure 2B), with IC50 value 0.6 nM for
BaF3-WT FIP1L1-PDGFRα and 2.8 nM for BaF3-T674I
FIP1L1-PDGFRα cells.
Cell cycle distribution was analyzed by flow cytometry
analysis of cellular DNA content after exposing the cells to
increasing concentrations of ponatinib for 24 h. Ponatinib
did not significantly change cell-cycle phase distribution
except for an increase in sub-G1 particles, indicative of
apoptosis (Figure 2C).
Figure 2 Ponatinib inhibits the growth of neoplastic cells expressing PDGFRα. (A) Ponatinib inhibited the cell viability of FIP1LI-PDGFRα-
expressing cells. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to increasing concentrations of ponatinib, sorafenib or imatinib
for 72 h, and cell viability was evaluated by MTS assay. Graphs show data from 3 independent experiments; error bars represent 95% confidence
intervals. (B) Clonogenicity of BaF3-WT or -T674I FIP1L1-PDGFRα cells was inhibited by ponatinib in a concentration-dependent manner. Error bars
represent 95% confidence intervals. (C) Effect of ponatinib on cell cycle distribution in CEL cells. CEL cells were exposed to ponatinib for 24 h.
Cells were fixed and analyzed by FACScalibur after staining with propidium iodide. Histograms are from representative experiments.
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and -resistant CEL cells by triggering the mitochondrial
apoptosis pathway
We next assessed whether ponatinib induced apoptosis.
The FIP1L1-PDGFRα-expressing cells were exposed toincreasing concentrations of ponatinib for 24 h, and
apoptosis was measured by Annexin V binding. Ponati-
nib led to remarkable apoptotic cell death in all 3 cell
lines (Figure 3A). Further, condensation of chromatin in
the periphery of the nuclei was observed by transmission
Figure 3 (See legend on next page.)
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Figure 3 Ponatinib induces apoptosis in FIP1LI-PDGFRα-expressing cells. (A) EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed
to increasing concentrations of ponatinib for 24 h, apoptotic cells were assayed with flow cytometry by PI/Annexin V-FITC (EOL-1) or 7-AAD/Annexin
V-PE (BaF3-WT or -T674I FIP1L1-PDGFRα cells) staining. Left, representative histograms; Right, statistical data of 3 independent experiments, the vertical
axis stands for the sum of all dead cells. Error bars represent 95% confidence intervals. **, P < 0.01; ***, P < 0.0001, one-way ANOVA, post hoc
comparisons, Tukey’s test. (B) The indicated cells were treated with or without ponatinib (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I
FIP1L1-PDGFRα cells, respectively) for 24 h, washed with PBS and fixed with 2% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer
(pH 7.3). Representative photographs (9700×) were acquired under transmission electron microscopy. (C) The concentration- (for 24 h) and
time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib
was analyzed by immunoblotting. (D) Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for
the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by
immunoblotting. (E) Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h.
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duction of apoptosis by ponatinib (Figure 3B). Moreover,
ponatinib induced concentration- and time-dependent
specific cleavage of PARP and caspase-3 activation in all
three FIP1L1-PDGFRα-expressing cell lines (Figure 3C).
Therefore, ponatinib could efficiently induce apoptosis
in CEL cells harboring WT or T674I FIP1L1-PDGFRα.
To identify the apoptotic pathway triggered by ponati-
nib, the cells were treated with ponatinib, and AIF and
cytochrome c in the cytosolic fraction were measured by
immunoblotting. Ponatinib induced a time-dependent
release of AIF and cytochrome c from the mitochondria
into the cytosol (Figure 3D). In assessing the effect of
ponatinib on the expression of apoptosis-related pro-
teins, immunoblotting analysis revealed a prominent de-
crease in protein levels of Mcl-1, survivin and Bcl-XL,
which are anti-apoptotic, with no effect on the levels of
other apoptosis-related proteins such as XIAP, Bax,
Bcl-2, and Bim (Figure 3E).
Ponatinib elicits caspase-3-dependent cleavage of Mcl-1
Because of the critical pro-survival role of Mcl-1 in
leukemia [22,23], we explored its role in ponatinib-
induced apoptosis of CEL cells. Mcl-1 mRNA levels did
not significantly differ between ponatinib-treated CEL
cells and controls (data not shown). Time chase experi-
ments with inhibition of de novo protein synthesis by cy-
cloheximide (CHX) revealed increased degradation of
Mcl-1 level in ponatinib-treated CEL cells as compared
with controls (Figure 4A). However, pretreatment with
MG-132 (a specific proteasome inhibitor) did not pre-
vent the ponatinib-induced degradation of Mcl-1 level
(Figure 4B), which suggests that ponatinib decreased
Mcl-1 level without involving proteasomes. Time-course
study revealed that loss of Mcl-1 (p42) was accompanied
by the appearance of a cleaved form Mcl-1 (p28) as apop-
tosis (specific cleavage of PARP) progressed (Figure 4C).
These data are in agreement with a report of Mcl-1 being
cleaved by caspase-3 at Asp127 to produce a 28-kDa
fragment (Mcl-1128-350) [24]. To further confirm that
ponatinib-induced Mcl-1 cleavage was caused by caspase-3
activation, CEL cells were treated with ponatinib in theabsence or presence of the caspase-3 inhibitor z-DEVD-
fmk. Immunoblotting revealed complete abrogation of
decreased Mcl-1 level (p42) and appearance of the
Mcl-1128-350 (p28) fragment (Figure 4D). Therefore,
ponatinib-induced activation of caspase-3 may cleave
and decrease the amount of Mcl-1.
Silencing Mcl-1 with specific siRNA duplex signifi-
cantly enhanced the cytotoxicity of ponatinib, as reflected
by PARP cleavage and cell death (Figure 4E). In contrast,
enforced overexpression of Mcl-1 by transfection at-
tenuated ponatinib-induced apoptosis in EOL-1 cells
(Figure 4F). Taken together, cleavage of Mcl-1 by
caspase-3 may form a positive feedback mechanism in
the induction of apoptosis of CEL cells by ponatinib.
Ponatinib inhibits tyrosine phosphorylation of PDGFRα
β-catenin, a critical effector in the canonical Wnt/β-catenin
signaling cascade widely involved in cell proliferation, differ-
entiation, escape of apoptosis and transformation [25], is a
substrate of tyrosine kinases such as PDGFRα, Bcr-Abl, Flt3,
and KIT [26-28]. Tyrosine phosphorylation of β-catenin
leads to increased protein stability, keeping β-catenin active
[26-29]. We therefore examined the potential change in
tyrosine phosphorylation of β-catenin as a result of inhib-
ition of PDGFRα by ponatinib. Because nuclear transloca-
tion of β-catenin is required for its functions (i.e., to activate
TCF/LEF), we first examined whether ponatinib affected the
subcellular distribution of β-catenin. With standard subcel-
lular fractionation protocols, the levels of β-catenin in cyto-
solic and nuclear fractions were dose-dependently lowered
by ponatinib (Figure 5A). Immunofluorescence analysis
further confirmed that β-catenin was decreased by ponatinib
in both cytosolic and nuclear compartments (Figure 5B).
Electrophoretic mobility shift assay (EMSA) also revealed
a concentration- and time-dependent decrease in nuclear
β-catenin with ponatinib treatment (Figure 5C). Time chase
experiments in the presence of CHX revealed that ponatinib
led to an increased degradation rate of β-catenin (Figure 5D).
Time-course study showed that the decrease in levels of
β-catenin occurred concurrently with tyrosine dephosphory-
lation in β-catenin after inactivation of PDGFRα by ponati-
nib (Figure 5E). EOL-1 cells transfected with siRNA against
Figure 4 Ponatinib mediates caspase-3-dependent cleavage of Mcl-1. (A) Ponatinib precipitated in Mcl-1 turnover. After pretreatment with or
without 1 nM ponatinib, EOL-1 cells were exposed to 5 μg/ml of cycloheximide (CHX), followed by Mcl-1 detection with immunoblotting. (B) MG-132
did not abrogate ponatinib-induced cleavage of Mcl-1. EOL-1 cells were treated with 1 nM ponatinib in the presence or absence of 0.5 μM MG-132 for
24 h. Mcl-1 level was then monitored with immunoblotting. (C) Mcl-1 cleavage occurred with onset of apoptosis after treatment with ponatinib. EOL-1
cells were treated with 1 nM ponatinib for different times, and the indicated proteins were measured with immunoblotting. (D) Mcl-1 cleaved in a
caspase-3-dependent manner. EOL-1 cells were treated with 1 nM ponatinib for 24 h with or without 10 μM z-DEVD-fmk, then underwent immunoblotting.
(E) Silencing Mcl-1 potentiated ponatinib-induced apoptosis in EOL-1 cells. Twenty-four hours after transfection with Mcl-1 siRNA or control (mock) siRNA,
EOL-1 cells were treated with various concentrations of ponatinib, and levels of Mcl-1, PARP, and actin were evaluated by immunoblotting (top); parallel
samples were examined for apoptosis by trypan blue staining (bottom, *** P< 0.0001, t test, error bars represent 95% confidence intervals; representative
data from 3 independent experiments are shown). (F) Enforced overexpression of Mcl-1 abrogated the ponatinib-induced apoptosis.
Twenty-four hours after transfection with pCMV5-flag empty vector or the plasmid expressing Mcl-1, EOL-1 cells were incubated with or
without concentrations of ponatinib for another 24 h. Cell viability was evaluated by trypan blue dye exclusion (lower, *** P < 0.0001, t test,
error bars represent 95% confidence intervals); Mcl-1 and PARP levels were detected by immunoblotting.
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catenin (Figure 5E, right), further supporting the specific ef-
fect of PDGFRα on β-catenin stability. These data support
that tyrosine phosphorylation in β-catenin by PDGFRα dir-
ectly promotes β-catenin stability.
Ponatinib inhibits TCF/LEF-dependent reporter gene
transcription
Nuclear β-catenin in complex with TCF/LEF transcription
factors can activate target genes whose promoter contains
the regulatory elements [30]. We therefore examined
whether ponatinib treatment influenced TCF/LEF-dependent
transcription. EOL-1 cells were cotransfected with TOPflash
(or FOPflash) and pEFRRenilla-Luc for 24 h, cultured withor without ponatinib for an additional 24 h, then luciferase
assay was performed. Ponatinib concentration-dependently
inhibited the luciferase activity of TOP promoter constructs
with optimized TCF-binding sites (Figure 5F). As a negative
control, the luciferase activity of FOP promoter constructs
with mutated TCF-binding sites was not changed.Ponatinib decreases the level of TCF/LEF-dependent
genes involved in proliferation
We next examined whether ponatinib inhibited the
expression of target genes (e.g. c-Myc and cyclin D1) of
β-catenin-TCF/LEF. Immunoblotting revealed EOL-1 cells
incubated with or without ponatinib for 24 h showing a
Figure 5 (See legend on next page.)
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Figure 5 Inhibition of tyrosine kinase activity of PDGFRα by ponatinib attenuates signaling of β-catenin by lowering its stability. (A) Ponatinib
concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined
by immunoblotting. (B) Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was
performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). (C) EOL-1 cells were pretreated with the indicated
concentrations of ponatinib for 24 h or 1 nM ponatinib for various durations; and the nuclear extracts were then assayed for TCF/LEF activation by
EMSA. (D) Ponatinib increased β-catenin turnover rate. After pretreatment with or without 1 nM ponatinib for 16 h, EOL-1 cells were exposed to
5 μg/ml of CHX, followed by immunoblotting for β-catenin. (E) Inhibition of PDGFRα decreased β-catenin. EOL-1 cells were treated with 1 nM
ponatinib for various times, then total and tyrosine-phosphorylated β-catenin were evaluated (Left) by immunoblotting. EOL-1 cells were transfected
with mock siRNA or PDGFRα siRNA, and β-catenin was monitored by immunoblotting. (F) Ponatinib abrogated TCF/LEF-dependent luciferase activity.
EOL-1 cells were transfected with TOPflash and FOPflash plasmids and pEFRenilla-luc. After 24 h, the cells were treated with ponatinib for another 24 h,
then underwent luciferase activity assay. (G) Ponatinib decreased the expression of target genes of β-catenin. Immunoblotting analysis in EOL-1 cells
that were exposed to ponatinib for 24 h. (H) Ectopically changing the levels of β-catenin affected the ponatinib-mediated apoptosis. Twenty-four hours
after transfection with control or Mcl-1 siRNA, or empty vector, pcDNA3-β-catenin, EOL-1 cells were treated with ponatinib, and the relevant protein
levels were evaluated by immunoblotting (left); parallel samples were examined by the trypan blue dye exclusion assay (right, *** P<0.0001, t test; error
bars represent 95% confidence intervals).
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D1 levels (Figure 5G).
β-catenin plays a significant role in ponatinib-induced
apoptosis
EOL-1 cells transfected with specific siRNA duplex against
β-catenin underwent remarkable apoptosis as comparedFigure 6 Ponatinib potently abrogates the growth of imatinib-resista
mouse xenografts. (A) BALB/c nu/nu nude mice were subcutaneously ino
groups (10 animals each) for daily oral administration of vehicle [30% Crem
after inoculation of cells. The tumor growth curves are plotted. Error bars repr
measured on day 21. ***, P < 0.0001, one-way ANOVA, post hoc comparisons
Representative tumors removed from mice of each group are shown (up
staining of xenograft tissues from mice sacrificed 21 days after tumor in
by ponatinib. Whole cell lysates prepared from xenografts of each groupwith cells transfected with control siRNA, as reflected by
PARP cleavage, caspase-3 activation and trypan-blue
staining (Figure 5H, left). In addition, silencing β-catenin
potentiated the sensitivity of EOL-1 cells to ponatinib
(Figure 5H, left). Conversely, EOL-1 cells transfected with
constructs encoding full-length β-catenin led to decreased
sensitivity of EOL-1 cells to ponatinib (Figure 5H, right).nt neoplastic cells expressing T674I FIP1L1-PDGFRα in nude
culated with BaF3-T674I FIP1L1-PDGFRα cells, then randomized into 3
ophor EL/ethanol (4:1), 70% PBS], imatinib or ponatinib during days 5–21
esent 95% confidence intervals. (B) Dissected tumor xenografts were
, Tukey’s test. Columns, mean; error bars, 95% confidence intervals.
per). (C) Immnunohistochemical analysis with anti-Ki67 and H & E
oculation. (D) The signaling of PDGFRα in tumor tissue was inhibited
were detected by immunoblotting with the indicated antibodies.
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FIP1L1-PDGFRα cells in nude mice
The in vivo antineoplastic activity of ponatinib as a single
agent against imatinib-resistant T674I FIP1L1-PDGFRα-
expressing cells was evaluated in the nude mouse xeno-
graft model. Thirty nu/nu BALB/c mice were subcutane-
ously injected with BaF3-T674I PDGFRα cells. Four days
later, when tumor sizes were ~50 mm3, the mice were ran-
domized to receive treatment with vehicle, imatinib (50
mg/kg/d) or ponatinib (30 mg/kg/d) for 15 days (n = 10).
The tumor growth curve (the estimated tumor size calcu-
lated from the tumor dimension versus time) with ima-
tinib was almost the same as with vehicle (Figure 6A),
which indicates in vivo resistance of BaF3-T674I PDGFRα
cells to imatinib. In contrast, ponatinib treatment abro-
gated the growth of tumors (Figure 6A). Tumor weight
did not differ between imatinib- and vehicle-treated tu-
mors but was lower in ponatinib-treated than control tu-
mors (Figure 6B). Cell proliferation, as reflected by
Ki67 immunohistochemistry, was inhibited by ponati-
nib (Figure 6C) as compared with the two controls.
Immunoblotting of cell lysates from tumors from
ponatinib-treated mice showed pronounced decreases
in phosphorylated PDGFRα, Stat5, Akt, and Erk1/2 but
not their total counterparts, so ponatinib blocked
PDGFRα signaling in xenografts (Figure 6D). In addition,
the level of β-catenin was decreased by ponatinib
(Figure 6D). The body weights of the mice remained
stable, with no significant differences between drug-
treated and control mice (data not shown). Motor ac-
tivity and feeding behavior of the mice were all nor-
mal. No mice died until the scheduled sacrifice.
Overall, ponatinib was well tolerated at the dosage
used.Discussion
Acquired resistance to TKIs presents a therapeutic chal-
lenge. Gatekeeper mutants (e.g. T315I Bcr-Abl, T670I
KIT and T674I PDGFRα) are particularly multi-drug re-
sistant. In the present study, ponatinib potently inhibited
the phosphorylation of the WT and gatekeeper mutant
T674I FIP1L1-PDGFRα and their downstream signaling.
Our molecular docking analysis revealed that ponatinib
could target native or T674I FIP1L1-PDGFRα in the
DFG-out (inactive) binding mode, similar to ponatinib
docking in T315I Bcr-Abl. This characteristic of ponati-
nib may be related to its imidazo [1,2b] pyridazine core
that occupies the pocket for adenine in the enzyme,
whereas the methylphenyl group occupies the hydropho-
bic pocket behind the gatekeeper residue of the enzyme
[15]. Encouraged by the in silico simulation results, we
evaluated the efficacy of ponatinib against imatinib-
resistant CEL cells both in vitro and in vivo.Ponatinib potently inhibit the viability of EOL-1 cells
expressing WT FIP1L1-PDGFRα, with an IC50 value of
0.004 nM. This efficacy agrees with recent results [20]
showing an inhibitory effect in EOL-1 cells, with an
IC50 of 0.5 nM. In the same study, ponatinib inhibited
malignant cells expressing Bcr-Abl, Flt3, KIT, FGFR1,
with IC50 values from 2 to 36 nM [20]. We showed
that ponatinib had an inhibitory effect on imatinib-
resistant leukemic BaF3-T674I FIP1L1-PDGFRα cells,
with an IC50 of 2.5 nM, which is comparable to the po-
tency in BaF3-T315I Bcr-Abl cells, with an IC50 of 11
nM [15]. Clonogenicity assay confirmed that ponatinib
restrained the proliferation of BaF3-WT or -T674I
FIP1L1-PDGFRα cells at low nanomolar concentra-
tions. Further, our in vivo data revealed that ponatinib,
at an oral dose of 30 mg/kg/day, potently abrogated the
growth of xenografted imatinib-resistant BaF3-T674I
FIP1L1-PDGFRα cells, with PDGFRα signaling highly sup-
pressed (Figure 6). A pharmacokinetics study in mice indi-
cated that orally administrated ponatinib as a single oral
dose of 30 mg/kg, which was well tolerated, resulted in
mean plasma concentrations of 782 and 561 nM at 2 and
6 h post-dosing, respectively [15]. Such plasma levels
highly exceed the in vitro IC50 values for all 3 lines of
FIP1L1-PDGFRα-expressing cells, so ponatinib may effi-
ciently inhibit the growth of FIP1L1-PDGFRα-positive
cells with clinically achievable doses.
Ponatinib induced remarkable apoptosis in both
imatinib-sensitive and -resistant CEL cells, as evidenced
by Annexin V binding, activation of caspase-3, and spe-
cific cleavage of PARP. The apoptosis was triggered by the
mitochondrial-dependent pathway because of release of
AIF and cytochrome c to the cytosol after treatment with
ponatinib. The levels of survivin, Bcl-XL and Mcl-1were
decreased in ponatinib-mediated apoptotic CEL cells. The
transcription of survivin and Bcl-XL is regulated by Stat3,
Stat5 and Erk1/2 [31,32]. The decreased expression of sur-
vivin and Bcl-XL caused by ponatinib treatment is likely
associated with the inhibition of Stat3, Stat5 and Erk1/2.
However, future experiments can further define the pre-
cise mechanisms.
Mcl-1, a pro-survival and anti-apoptotic protein with
relatively short-half life in the Bcl-2 family, is expressed in
malignant hematological cells and protects cells against
apoptosis in response to chemotherapeutic agents includ-
ing TKIs [22,33]. The decrease in Mcl-1 by ponatinib in
CEL cells may facilitate apoptosis, because silencing
Mcl-1 with siRNA significantly potentiated the ponatinib-
mediated apoptosis in EOL-1 cells, which is in line with
the finding that decreased Mcl-1 level sensitizes leukemia
cells to tyrosine kinase inhibitors [22]. Forced overexpres-
sion of Mcl-1 protected CEL cells against apoptosis in re-
sponse to ponatinib. Regarding the mechanism underlying
the decrease in Mcl-1 level by ponatinib, our results do
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and transcription-dependent pathways. Rather, our data
support a caspase-3-dependent mechanism, which is con-
sistent with findings for other small-molecule tyrosine
kinase inhibitors [9]. Of note, the resulting truncated form
of Mcl-1128–350 (p28) cleaved by activated caspase-3 can
potentiate apoptosis [24,34]. Mcl-1128–350 (p28) after
ponatinib treatment likely produces a positive feedback
to apoptosis. Although Bim has been reported as the
primary death effector in TKIs-treated CML cells [35],
no appreciable change was noted in ponatinib-treated
CEL cells in the present study. However, because Mcl-1
has been demonstrated to neutralize Bim through com-
plex formation to prevent apoptosis, our observed decline
in Mcl-1 by ponatinib would increase the Bim/Mcl-1 ratio,
which may release Bim to promote apoptosis [36].
The observed decrease in β-catenin induced by ponati-
nib exposure may be important because of the funda-
mental functions of β-catenin in cell proliferation,
differentiation and apoptosis. [25]. Besides accumulating
in a Wnt/GSK3β-dependent way, β-catenin may also
accumulate after phosphorylation by tyrosine kinases
(e.g., Bcr-Abl, RET, KIT, Flt3, PDGFRα) [26-28,37]. In-
activating PDGFRα by treating EOL-1 cells with pona-
tinib inhibited tyrosine phosphorylation (Y654) and
concurrently decreased levels of β-catenin, as reflected
by immunoblotting and immunofluorescent staining
(Figure 5). Silencing PDGFRα also lowered β-catenin
level, which further supports the specificity of the ef-
fect of PDGFRα on the levels of β-catenin. The turn-
over rate is enhanced in EOL-1 cells pretreated with
ponatinib. Of note, inactivation of PDGFRα by ponati-
nib decreased β-catenin level in both cytosolic and nu-
clear pools. Ponatinib also decreased β-catenin level in
xenografts in in vivo experiments.
The decrease in β-catenin level by ponatinib has func-
tional consequences. First, TCF/LEF-dependent gene tran-
scription was impaired in EOL-1 cells treated with
ponatinib. Second, the expression of β-catenin-dependent
genes such as c-Myc and cyclin D1 was decreased. Third,
the binding of β-catenin and DNA was also decreased, as
revealed by EMSA. Because β-catenin plays a crucial role
in controlling self-renewal and differentiation in both nor-
mal and cancer stem cells [25], a decrease in β-catenin
level may be an important aspect of the antineoplastic
mechanism of ponatinib. An interesting hypothesis for fu-
ture research is whether decreased β-catenin can facilitate
the eradication of cancer stem cells.
While this manuscript was under review, Lierman
et al. reported that ponatinib was active against
imatinib-resistant FIP1L1-PDGFRα mutants [38]. Our
results corroborated and extended their findings by pro-
viding a mechanism for the induction of apoptosis and
evidence for in vivo efficacy.Conclusions
In conclusion, ponatinib is a potent inhibitor against both
WT and T674I FIP1L1-PDGFRα. Caspase-3-dependent
Mcl-1 cleavage may be a positive feedback mechanism to
enhance apoptosis in ponatinib-treated cells. Inhibition of
PDGFRα activity by ponatinib leads to decreased tyrosine
phosphorylation of β-catenin, decreased protein stability
and protein level of β-catenin, decreased transcription of
TCF/LEF-regulated genes, and enhanced cytotoxicity.
Therefore, regulation of β-catenin by PDGFRα plays a role
in the antineoplastic mechanism of ponatinib. Given the
FDA approval of oral ponatinib in patients with refractory
CML and Ph +ALL resistant to the first- and second-
generation of TKIs [39], our findings warrant a clinical
trial of ponatinib in imatinib-resistant CEL and other ma-
lignant disorders harboring T674I PDGFRα.
Materials and methods
Reagents
Ponatinib (purity > 95%, HPLC) was synthesized in our
lab. Imatinib and sorafenib were purchased from Alexis
Biochemicals (Plymouth Meeting, PA). 4′, 6-diamidino-
2-phenylindole (DAPI) was from Invitrogen. Cyclohexi-
mide (CHX) and propidium iodide (PI) were from
Sigma-Aldrich. TOPflash/FOPflash system consisting of
optimized TCF binding sites (TOP) or mutated sites
(FOP) controlling the expression of a luciferase reporter
gene was from Upstate Biotechnology (Lake Placid, NY).
pCMV5-flag-human Mcl-1 and pcDNA3-β-catenin were
kindly provided by Dr. Mien-Chie Hung (The University
of Texas MD Anderson Cancer Center, Houston, TX)
[40]. ON-TARGETplus SMARTpool small interfering
RNA (siRNA) duplexes against human Mcl-1 or PDGFRα,
and Non-Targeting Pool siRNA control were from Dhar-
macon RNATech. (Lafayette, CO) [8,41].
Cell culture and cell growth measurement
The EOL-1 cell line harboring the FIP1L1-PDGFRα fusion
oncogene was purchased from DMSZ (Braunschweig,
Germany). BaF3 cells expressing WT or T674I FIP1L1-
PDGFRα were cultured as described previously [8,9].
Cell viability was assessed by MTS assay (CellTiter 96
Aqueous One Solution reagent, Promega, Shanghai) [40,42].
Clonogenicity assay was performed as described [40].
In brief, 2×105/ml cells were treated with drugs or dilu-
ent (DMSO, control) for 24 h, then washed with PBS
and seeded in methylcellulose medium (Methocult M3231,
Stem Cell Technologies, Vancouver, Canada) [40]. After
incubation for ~7 days at 37°C and 5% CO2, colonies
with >50 cells were counted [40].
Preparation of whole cell lysates and cytosolic fraction
Most experiments of immunoblotting involved whole ly-
sates prepared with RIPA buffer unless otherwise stated
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in the cytosol, the cytosolic extract was prepared with
digitonin extraction buffer [42,43].
Preparation of cytoplasmic and nuclear fractions
Distribution of β-catenin was determined in the cyto-
plasmic and nuclear fractions as we previously de-
scribed [44].
Immunoblotting
Immunoblotting involved use of whole cell lysates pre-
pared in RIPA buffer [8,9,40]. Antibodies and their
sources were as follows: antibodies against apoptosis-
inducing factor (AIF), Mcl-1 (S-19), Bax and Bcl-XL
(Santa Cruz Biotechnology, Santa Cruz, CA); antibodies
against poly(adenosine diphosphate [ADP]-ribose) poly-
merase (PARP), X-linked inhibitor of apoptosis (XIAP),
caspase-3, active caspase-3, cytochrome c (clone 6H2.
B4), survivin, and C-terminal β-catenin (BD Biosciences
Pharmingen, San Jose, CA); phospho-β-catenin (Y654)
(Abcam, Cambridge, MA); antibodies against phospho-
PDGFRα (Y1018), phospho-Erk1/2 (T202/Y204) and Erk1/
2 (Cell Signaling Technology, Beverly, MA); antibodies
against phospho-Stat3 (Y705), phospho-Stat5A/B (Y694/
Y699), Stat3, Stat5, Bcl-2 and PDGFRα (Upstate Tech-
nology, Lake Placid, NY); anti-Bim (Stressgen, Ann
Arbor, MI); anti-actin (Sigma-Aldrich, Shanghai). Anti-
mouse immunoglobulin G and anti-rabbit immunoglobu-
lin G horseradish peroxidase-conjugated antibodies were
from Pierce Biotechnology (Rockford, IL, USA).
Plasmids or small interfering RNA transfection
EOL-1 cells were transfected with plasmids or siRNA du-
plexes with use of Nucleofector (Amaxa, Gaithersburg,
MD) by use of the Cell Line Nucleofector Kit T (Amaxa)
and program O-17 [8]. At 24 h after transfection, EOL-1
cells were adjusted to 2×105/ml and exposed to ponati-
nib treatment, then underwent cell death assay and
immunoblotting.
Luciferase assay
EOL-1 cells (2×105) were transfected with TOPflash or
FOPflash plasmid (0.5 μg) and pEFRenilla-luc (10 ng) by
electroporation. At 24 h, cells were incubated with or
without ponatinib for 24 h. Luciferase activity was then
measured with the dual-luciferase assay kits (Promega,
Shanghai) as described [45].
Electrophoretic mobility shift assay (EMSA)
EMSA involved the LightShift Chemiluminescent EMSA
kit (Pierce Biotechnology, Shanghai). The oligonucleo-
tides for TCF/LEF were from Promega (Shanghai) with
sequences as described [46]: forward, 5-TGCCGGGCTT
TGATCTTTG-3; reverse, 5-AGCAAAGATCAAAGCCCGG-3. In brief, oligonucleotides for TCF/LEF were la-
beled with biotin by use of the biotin 3′-end DNA label-
ing kit (Pierce Biotechnology, Shanghai). In total, 5 μg of
nuclear extracts was incubated for 20 mins with 1 μg/μl
poly(dI-dC) and biotin end-labeled target nucleotides in
20-μl reaction mixtures. The resulting bound complex
was separated from free oligonucleotides on 6% native
polyacrylamide gel and transferred to a nylon membrane.
After cross-linking, blocking, and reacting with substrates,
the membranes were exposed to X-ray film to detect
biotin-labeled DNA. The binding specificity was examined
by competition with a 200-fold excess of the unlabeled
oligonucleotide probe (cold competitor) [40,47].
Transmission electron microscopy
The cells were treated with or without ponatinib, and
then fixed with 2% glutaraldehyde plus 2% paraformalde-
hyde in 0.1 M cacodylate buffer (pH 7.3). After washing,
and postfixing, the samples were dehydrated and embed-
ded in Spurr’s low-viscosity medium [48]. Ultrathin sec-
tions of the samples stained with uranyl acetate and lead
citrate were examined under a JEM 1010 transmission
electron microscope [48].
Immunofluorescence staining
EOL-1 cells were treated with or without ponatinib for
24 h, and then harvested by use of Cytospin onto glass
slides. Immunofluorescence staining was as described
[42]. DyLight 488 conjugated-goat-anti-mouse immuno-
globulin was purchased from Pierce Biotechnology
(Rockford, IL).
Apoptosis assessment
Apoptosis was evaluated by using an Annexin V-fluorescein
isothiocyanate (for EOL-1) or Annexin V-phycoerythrin (for
BaF3 cells expressing FIP1L1-PDGFRα) apoptosis detection
kit (BD Biosciences Pharmingen, San Jose, CA) and analyzed
by using a FACSCalibur flow cytometer [8,9,40].
Cell cycle analysis
Control or ponatinib-treated cells were fixed with 66%
ethanol overnight. DNA content was analyzed by flow
cytometry after cells were stained with 50 μg/ml PI and
2.5 μg/ml RNase in PBS solution for 30 mins [42,43].
Tumor xenograft experiments
Male nu/nu BALB/c mice were bred at the animal facil-
ity of Sun Yat-sen University. An amount of 1×107
BaF3-T674I PDGFRα cells supplemented with 50% matri-
gel was inoculated subcutaneously on the flanks of 4~6-
week-old male nude mice. Tumors were measured every
other day with calipers. Tumor volumes were calculated
by the following formula: a2 × b × 0.4, where a is the
smallest diameter and b is the diameter perpendicular to
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adjusted to the appropriate doses with vehicle [30%
Cremophor EL/ethanol (4:1), 70% PBS], and imatinib
was dissolved in sterile double-distilled water. Mice in
each group were treated once daily by oral gavage with
ponatinib, imatinib or the same amount of vehicle.
The body weight, feeding behavior and motor activity
of each animal were monitored as indicators of general
health. Tumor xenografts were immediately removed,
weighed, stored and fixed after animals were killed. All
animal studies were conducted with the approval of
the Sun Yat-sen University Institutional Animal Care
and Use Committee.
Immunohistochemical staining
Formalin-fixed BaF3-T674I FIP1L1-PDGFRα-cell xeno-
grafts were embedded in paraffin, sectioned (4-μm thick),
then immunohistochemically stained by using the anti-
Ki67 MaxVision kit (Maixin Biol, Fuzhou, China). Color
was developed with 0.05% diaminobenzidine and 0.03%
H2O2 in 50 mM Tris–HCl (pH 7.6), and slides were coun-
terstained with hematoxylin [47].
Homology modeling
The kinase domain sequence was identified from the
Human Kinome database [49] by sequence alignment of
the kinase domain within the full-length PDGFRα se-
quence (NCBI protein database, GI: 1736333) and the
site to be mutated by use of CLUSTAL X [50].
Prime module in Maestro (Schrödinger Inc., v7.5) was
chosen to build homology models for the native kinase
domain sequence and the mutated sequence. We per-
formed a BLAST search against the PDB database to
choose a suitable template; the 1.6 Å X-ray structure of
KIT kinase (PDB code: 1 T46) in complex with imatinib
was chosen (identity 61%, E-value 4.1e-65) [51]. After
SSP modification and alignment editing in Prime, native
and mutated kinase models were built with default par-
ameter sets, followed by loop refinement and energy
minimization to eliminate and correct disallowed torsion
angles and unfavorable atom-atom conflicts.
Molecular docking
The compound ponatinib was prepared by the Ligprep
module, then the Glide module. Then docking simulations
were performed to test binding of ponatinib to the native
kinase model and the mutated one with the same default
parameter sets. The grid-enclosing box was centered on the
centroid of the aligned ligand (imatinib) and defined to en-
close residues located within 20 Å around the ATP binding
site; a scaling factor of 1.0 was set to van der Waals (VDW)
radii of the receptor atoms with the partial atomic charge
< 0.25. The Extra-Precision (XP) mode of Glide was used
to dock ponatinib into the ATP binding site with defaultparameters, and the top 10 docked poses were reserved
for the binding mode analysis.
Statistical analysis
All experiments were performed at least 3 times, and re-
sults are reported as mean ± 95% confidence intervals,
unless otherwise stated. GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA) was used for statistical ana-
lysis. A P < 0.05 was considered statistically significant.
Additional file
Additional file 1: Computer-simulated binding of ponatinib to the
native or mutated PDGFRα kinase in DFG(Asp-Phe-Gly)-out state.
The explanation was described in the fulltxt.
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